Guardant Health Inc (GH) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

MIXED

Guardant Health's (GH) growth stock status is facing skepticism due to concerns about its ability to sustain current growth rates. Analysts are highlighting potential headwinds related to free cash flow margins and return on invested capital (ROIC), which could impact valuation multiples. The company's cash runway is also a point of consideration, as a shorter runway may increase the risk of future dilution for investors. These factors warrant close attention as they could influence GH's long-term investment appeal. Investors should monitor future earnings reports and management commentary for updates on these key financial metrics.

GH|Company Info

Sector

Healthcare

Industry

Diagnostics & Research

Exchange

NMS

Country

United States

Website

guardanthealth.com

Symbol

Description

Guardant Health is a precision oncology company specializing in blood and tissue-based tests designed to improve cancer care. The company's core offering, the Guardant360 platform, provides comprehensive genomic profiling, including liquid biopsy and tissue-based tests, to inform treatment decisions. These tests, like Guardant360 CDx and Guardant Reveal, are utilized across the cancer care continuum, from initial diagnosis to monitoring treatment response and detecting recurrence. Guardant Health also offers advanced research tools like GuardantINFINITY and GuardantINFORM, supporting advancements in cancer therapy development. With its headquarters in Palo Alto, California, the company's integrated approach aims to provide actionable insights for both clinical and biopharmaceutical customers.

GH|Earnings Snapshot

Earnings Summary

Guardant Health is a precision oncology company focused on developing and commercializing blood and tissue-based diagnostic tests to improve cancer care. Operating within the Healthcare sector, specifically in Diagnostics & Research, the company's offerings, such as Guardant360, aim to provide comprehensive genomic profiling for treatment decisions. The company's recent performance shows a trend of accelerating revenue growth, with reported revenues increasing from $201.81 million in Q4 2024 to $301.67 million in Q1 2026. Concurrently, the company has demonstrated a consistent improvement in its earnings per share (EPS) performance, moving from a reported EPS of -0.62 in Q4 2024 to -0.45 in Q1 2026, indicating a deceleration in losses. Guardant Health has exceeded analyst EPS estimates in the last three reported quarters (Q1 2025, Q2 2025, Q3 2025) and also beat revenue estimates in Q4 2025 and Q1 2026, suggesting a positive beat pattern in recent periods. Historically, the company has shown year-over-year revenue growth, though EPS has remained negative, indicating ongoing investment in growth. A notable recent development includes FDA clearance for its first genomic-epigenomic liquid biopsy panel, a significant advancement that could drive future growth and investor optimism. However, concerns persist regarding cash burn, negative earnings, and recent insider selling, which investors should monitor alongside the commercial uptake of new diagnostic tools. Key watch points for the next quarter will include the continued acceleration of revenue growth and further improvement in EPS, as well as management's commentary on cash flow generation and the impact of the newly cleared liquid biopsy panel on clinical adoption and financial performance.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$-0.39	-	-
Q1'26	$-0.78	$-0.45	+42.1%
Q4'25	$-0.72	$-0.50	+30.1%
Q3'25	$-0.49	$-0.39	+20.3%
Q2'25	$-0.51	$-0.44	+14.5%
Q1'25	$-0.59	$-0.49	+17.0%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$323M	-	-
Q1'26	$288M	$302M	+4.9%
Q4'25	$279M	$281M	+0.9%
Q3'25	-	$265M	-
Q2'25	-	$232M	-
Q1'25	-	$203M	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

GH Stock Snapshot

GH is currently trading at $120.00, giving Guardant Health Inc a market cap of 15.77B. Today's range spans $114.00–$120.35, with shares opening at $118.95 and moving up $0.25 (0.2%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 52/100.

Over the past year GH has traded between $36.36 and $121.01 - the current price is +230.0% off the 52-week low and -0.8% from the high. 35 analysts cover the stock with a Buy consensus and a mean 12-month target of $130.52 (range $90.00–$190.00), implying upside of +8.8%.

Cross-asset context supports the bullish read on GH: when Healthcare sector conditions are favorable, large-cap names with 95/100 technical scores (BUY) and neutral sentiment (52/100) outperform on a risk-adjusted basis. Price: $120.00 (near 52-week highs). The 52-week context of $36.36–$121.01 shows the full trading history - and the current setup is one of the stronger entries within that range. At 15.77B in market cap, position sizing is the key variable, not the direction.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (95/100) and news sentiment (52/100, neutral) supports the narrative, analyst upgrades follow price rather than lead it. At $120.00 (near 52-week highs), GH's position within the $36.36–$121.01 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

News Sentiment Analysis

Sentiment gathered from recent headlines

52/100

Strong NegativeNeutralStrong Positive

MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Chris Freeman, Chief Commercial Officer at Guardant Health (GH), divested shares valued at approximately $2.89 million on May 22, 2026. This transaction, disclosed via a recent SEC filing, represents a significant insider sale. Investors will be monitoring any further insider activity and the company's strategic response to market dynamics.

What did this article say?

This article expresses skepticism regarding Guardant Health's (GH) growth stock status, citing potential challenges in sustaining growth and its impact on valuation multiples. The analysis highlights concerns about free cash flow margins, return on invested capital (ROIC), and cash runway as potential headwinds. Investors are advised to consider these factors when evaluating GH's long-term investment appeal.

What did this article say?

BTIG analyst Mark Massaro has reiterated a Buy rating on Guardant Health (GH) and increased the price target from $145 to $155. This action signals continued confidence from the analyst in the company's growth prospects and market position. Investors will be watching for further validation of this optimistic outlook.

What did this article say?

Deep Track Capital significantly increased its holdings in Structure Therapeutics (GPCR) during the first quarter, adding shares valued at approximately $11.50 million. This move positions GPCR as a notable holding within the fund's portfolio, which also includes substantial investments in GH. The article highlights GPCR's impressive 60% stock price appreciation over the past year, outperforming the broader market.

What did this article say?

Guardant Health (GH) has experienced a significant share price increase, rising approximately 25% in the past week and 33% over the last month. This surge brings its year-to-date gain to 16.9% and its one-year total shareholder return to 213%. The company is currently valued at $15.6 billion with $1.08 billion in revenue and a reported net loss of $433.2 million. Analysts suggest a potential undervaluation, with a fair value estimate of $128.33 per share.

What did this article say?

Guardant Health (GH) has received FDA clearance for its first genomic-epigenomic liquid biopsy panel, a significant development for the company and the field of cancer diagnostics. This approval marks a key milestone, potentially expanding the utility of liquid biopsies in clinical settings. The market reaction suggests renewed investor confidence in GH's growth trajectory and technological advancements. Investors will be closely watching the commercial uptake and clinical impact of this new panel.

What did this article say?

Guardant Health (GH) is highlighted as a stock with significant Wall Street upside potential, driven by its liquid biopsy technology. However, independent analysis raises concerns regarding its modest revenue base, cash burn, and negative earnings profile, questioning the sustainability of its long-term growth. The article suggests that while analysts are generally bullish, their ratings may be influenced by business relationships, prompting a closer look at the company's fundamentals.

What did this article say?

An insider at Guardant Health (GH) has divested shares valued at approximately $735,049. This transaction was recently reported in a filing with the Securities and Exchange Commission. The sale represents a notable transaction by an individual with non-public knowledge of the company's operations. Investors will monitor any further insider activity for potential directional signals.

What did this article say?

A substantial insider sale has occurred at Guardant Health (GH), with shares worth over $23 million changing hands. This significant divestment was disclosed in a recent filing with the SEC. Such a large transaction by an insider warrants attention for its potential implications on market sentiment. Traders should observe if this sale is part of a broader pattern or a singular event.

What did this article say?

Guardant Health (GH) has seen an insider sell shares totaling more than $2.1 million, as per a recent SEC filing. This transaction adds to recent insider selling activity reported for the company. The scale of this sale suggests a potential rebalancing of holdings or other personal financial decisions by the insider. Monitoring future insider transactions and company performance remains crucial.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

GH·Guardant Health Inc

EPS

Revenue

GH Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More